XIAP and inflammatory bowel disease: If validated, these findings may be valuable for predicting and preventing engraftment failure in IBD patients following the allo-HSCT, particularly for those with deficiency in XIAP and FOXP3. We are interested in further investigating the precise biological mechanism and the clinical impact of these microbiota using new technologies.